Drug Trial Radar · NCT06989983
A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462
Last checked: Nov 19, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
May 20, 2025
Primary completion
Jun 25, 2025
Study completion Jun 25, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Quotient Sciences
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to investigate how the body breaks down and gets rid of the test medicine, AZD5462. To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14), which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.
Conditions
- Heart Failure
Interventions
AZD5462 film-coated tabletDrug
Oral, fasted
[14C]AZD5462 Solution for InfusionDrug
Intravenous, fasted
[14C]AZD5462 Oral SolutionDrug
Oral, fasted
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amount of AZD5462 excreted (Ae) - Period 1Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
- Amount of AZD5462 excreted expressed as a percentage of the dose administered (Fe) - Period 1Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
- Cumulative amount of AZD5462 excreted (CumAe) - Period 1Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
- Cumulative amount of AZD5462 excreted expressed as a percentage of the dose administered (CumFe) - Period 1Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
- Absolute bioavailability - Period 2Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Ruddington, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.